Krystal Biotech, Inc. (KRYS) financial statements (2021 and earlier)

Company profile

Business Address 2100 WHARTON STREET
PITTSBURGH, PA 15203
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:194203196107524647
Cash and cash equivalents18819518798474247
Short-term investments6      
Other undisclosed cash, cash equivalents, and short-term investments089964 
Other undisclosed current assets2111100
Total current assets:196204196108534648
Noncurrent Assets
Operating lease, right-of-use asset33  
Property, plant and equipment8764200
Long-term investments and receivables0      
Long-term investments0      
Other noncurrent assets1000 0 
Other undisclosed noncurrent assets  33   
Total noncurrent assets:131098200
TOTAL ASSETS:209214205116544648
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1111100
Accounts payable1111000
Accrued liabilities0000000
Debt00     
Other liabilities0001   
Other undisclosed current liabilities2231100
Total current liabilities:3443210
Noncurrent Liabilities
Long-term debt and lease obligation33     
Operating lease, liability33  
Liabilities, other than long-term debt    0  
Other liabilities    0  
Other undisclosed noncurrent liabilities  33   
Total noncurrent liabilities:33330  
Total liabilities:6776210
Stockholders' equity
Stockholders' equity attributable to parent203208198109524547
Additional paid in capital242241228134695959
Accumulated other comprehensive income (loss)00000(0) 
Accumulated deficit(39)(34)(29)(24)(16)(13)(11)
Total stockholders' equity:203208198109524547
TOTAL LIABILITIES AND EQUITY:209214205116544648

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Operating expenses(6)(5)(6)(5)(3)(2)(2)
Operating loss:(6)(5)(6)(5)(3)(2)(2)
Nonoperating income  11000
Net loss:(6)(5)(5)(4)(3)(2)(2)
Other undisclosed net income attributable to parent11     
Net loss available to common stockholders, diluted:(5)(4)(5)(4)(3)(2)(2)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Net loss:(6)(5)(5)(4)(3)(2)(2)
Comprehensive loss:(6)(5)(5)(4)(3)(2)(2)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent11000(0) 
Comprehensive loss, net of tax, attributable to parent:(5)(4)(5)(4)(3)(2)(2)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: